Atrium Therapeutics

Company

Last mentioned: Mar 3, 2026

Timeline

Mar 15, 2026
Expected Rebalancing

Passive funds expected to complete divestment of RNAM shares to match new index weights.
Mar 3, 2026
S&P Index Deletion

S&P Dow Jones Indices removes RNAM from Global BMI and TMI benchmarks.
Feb 27, 2026
Novartis Deal Closure

Avidity finalizes agreement with Novartis, launching Atrium Therapeutics spinout.

Stories mentioning Atrium Therapeutics 1

Avidity Biosciences Exits S&P Indices Amid Strategic Shift and Novartis Deal

Avidity Biosciences (RNAM) has been removed from the S&P Global BMI and S&P TMI indices, effective March 2026. This technical deletion follows a major strategic milestone involving a deal closure with Novartis, signaling a period of significant structural transition for the biotech firm.

Mar 3, 2026 2 sources